About this Research Topic
Cancer causes more than 9.6 million deaths around the world each year. Despite novel therapeutic methods and improvements in clinical care in recent decades, cancer remains a significant public health burden. One of the difficulties in successful cancer treatment design is the tumor heterogeneity and lack of valid biomarkers to guide the prognosis and therapy.
With the advances in high-throughput (HTP) technologies such as gene microarray and next-generation sequencing, genomic, epigenomic and transcriptomic data of patients are available via public databases such as The Cancer Genome Atlas (TCGA), and Gene Expression Omnibus (GEO). These data sets are great resources that offer additional opportunities in biomarker discovery and validation. Unfortunately, their potential is not fully utilized as and analysis of stored information requires researchers to have a strong background in bioinformatics. Therefore, there is a need for user-friendly online tools and web servers providing such support for investigators involved in oncology biomarker discovery studies.
This Research Topic welcomes manuscripts that develop biomarker related tools, databases and web servers that assist clinical and basic science researchers in biomarker development and validation. Specifically, potential topics should include but are not limited to the following:
(1) Bioinformatics software/algorithms for cancer biomarker screening.
(2) Online tools/web servers for convenient cancer biomarker test and validation.
(3) Databases for collecting and annotating cancer biomarkers.
We welcome Original Research articles, Technology Reports, as well as Review articles.
Keywords: Diagnosis, Prognosis, Therapy Response Prediction, Bioinformatics, Cancer
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.